I think that this appointment is to be welcomed. Not sure what...

I think that this appointment is to be welcomed.
Not sure what dakfifty is on about - the share price of 42c was never sustainable given the past performance of the business. It would appear that the Medivet acquisition has its problems and was not as good a purchase as was first thought to be. Seems like dakfifty is aligned with, or was part of, the old management team and chairman.
Whilst we would all like to see the share price north of 7c, it is better that this occur as a result of performance rather than spin. Under this new leadership the company recorded its first annual profit; has had a profitable first quarter; and, based upon the AGM, this would seem to be on-going - something that the former management was never able to achieve. Also it is interesting to note that Hancox made a big point about the good performance of the human health side of the business - something that appears to have been neglected in recent times.
What to look forward to? The 2nd quarter and the half year results should provide more evidence to support the turnaround. It will also be interesting to see how the company proposes to use the proceeds from the rights issue. Better times ahead is my guess.